Hepatitis B Virus News and Research

RSS

Hepatitis B virus prevalent among Asians in NY

Approximately 15% of Asians living in New York City are chronically infected with hepatitis B virus, according to a new study by New York University School of Medicine researchers and their colleagues.

23 May 2006

15% of Asians living in New York City are chronically infected with hepatitis B virus

Chronic hepatitis B infection usually will lead to liver inflammation and can progress to cirrhosis and liver cancer. The reported infection rate is 35 times higher than the rate in the general U.S. population.

12 May 2006

Trial of hepatitis C vaccine underway

Human clinical trials involving investigational vaccines to prevent Hepatitis C are rare. In the fall of 2003 there was a first-ever study at Saint Louis University Center for Vaccine Development, and an earlier small study at Johns Hopkins School of Medicine.

8 May 2006

Saint Louis University hunt for a Hepatitis C vaccine

3 May 2006

Outcome of patients with hepatitis B and HIV infections referred for liver transplantation

A new study on HIV patients who also had Hepatitis B virus (HBV) found that better outcomes are possible if they are referred early for transplant and treated with a combination of drugs for HBV. It is essential to monitor the HBV status of these patients, however, in order to control the emergence of drug-resistant HBV infection.

3 May 2006

Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C

Cirrhosis related to non-alcoholic steatohepatitis (NASH) is associated with fewer complications and a lower mortality compared to cirrhosis from hepatitis C, despite NASH patients' greater risk of dying from cardiovascular events.

11 Apr 2006

New approach to treating hepatitis C virus

Last year Peter Sarnow, PhD, professor of microbiology and immunology at the Stanford University School of Medicine, identified a previously unknown mechanism that the hepatitis C virus uses to replicate, yielding a promising new approach to combating the disease-causing virus.

10 Apr 2006

New vaccines will protect against cancer

The leading cancer charity in Britain is predicting that thousands of cancers will be prevented every year as specific vaccines are developed.

13 Mar 2006

New hepatitis drug much more effective

Chronic infection with the hepatitis B virus (HBV) is responsible for an enormous burden of disease throughout the world, including up to half of all cases of cirrhosis, end-stage liver disease, and hepatocellular carcinoma, a cancer of the liver.

9 Mar 2006

Prison Hepatitis program shows promise in limiting spread of HCV

In an article published in the Journal of Correctional Health Care, researchers from the National Development and Research Institutes, Inc. (NDRI) reported on an evaluation of an intervention program within a prison system addressing Hepatitis C virus (HCV).

6 Mar 2006

Lamivudine helps avoid Hepatitis B relapse during chemotherapy

A new study on treating hepatitis B patients who have cancer with an antiviral drug at the same time as they undergo chemotherapy found that the treatment helped prevent relapse of hepatitis B.

12 Feb 2006

Discovery of the molecular mechanism that inhibits HCV replication in vitro

Since its discovery several decades ago, the insidious human pathogen has stymied the quest for anti-viral therapies by refusing to reproduce in test tubes for more than a few hours or days, denying scientists an efficient virus production and infection system for experimental research.

7 Feb 2006

Call for public health intervention to treat young injection drug users infected with the hepatitis C virus

In a recent study published in the journal Clinical Infectious Diseases, scientists from New York City, Baltimore, Seattle, and San Diego called for an immediate public health intervention to treat young injection drug users infected with the hepatitis C virus (HCV).

7 Feb 2006

Researchers use new approach to 'break the code' for liver cancer test

Scientists at Birmingham University are using cutting edge technologies to move closer to a blood test that will improve early diagnosis of liver cancer in high risk groups, according to research published in the British Journal of Cancer.

25 Jan 2006

New real-time test for Chlamydia and Gonorrhea

Abbott today announced that a highly sensitive new test for the simultaneous detection of the sexually transmitted pathogens Chlamydia trachomatis (CT) and Neissera gonorrhoeae (NG) has received CE Mark certification, allowing it to be marketed in the European Union.

23 Jan 2006

Vaccine candidate for hepatitis C

Researchers at the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine candidate for hepatitis C, leading to hope in the fight against a disease for which no vaccines are yet available.

11 Jan 2006

Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation

Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.

5 Jan 2006

Limitation of combination therapy of Interferon and Ribavirin for older patients with chronic hepatitis C

A new Japanese study examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group.

5 Jan 2006

Largest hepatitis-C U.S. study defines optimal therapy

Final results of the WIN-R trial,[1] the largest hepatitis C study conducted in U.S. patients, showed that weight-based REBETOL (ribavirin, USP) in combination therapy with PEG-INTRON (peginterferon alfa-2b) achieved significantly higher rates of sustained virologic response (SVR)[2] and lower rates of relapse compared to the combination therapy using a flat dose of ribavirin.

14 Nov 2005

HIV-positive patients have shorter survival periods while awaiting liver transplants

A new study on HIV-positive patients eligible for liver transplants found that their survival while waiting for a transplant is significantly shorter than patients who are HIV-negative.

7 Nov 2005